Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426673 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.
A Phase 1 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00426673 is a Phase 1 study that has completed, run by UCB Pharma. The registered enrollment target is 15 participants.
The verdict
NCT00426673, a Phase 1 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of this Phase I study in 15 adult subjects suffering from epilepsy and chronically treated with phenytoin monotherapy is to evaluate the effect of steady-state ucb 34714 administration on the steady-state plasma levels of phenytoin.
Interventions
- DRUG Brivaracetam (ucb34714)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426673
The ClinicalTrials.gov registry entry for NCT00426673 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam (ucb34714) is the first listed.
NCT00426673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426673 about?
NCT00426673 is a clinical study titled "An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.". The primary objective of this Phase I study in 15 adult subjects suffering from epilepsy and chronically treated with phenytoin monotherapy is to evaluate the effect of steady-state ucb 34714 administration on the steady-state plasma levels of phenytoin.
What is the current status of trial NCT00426673?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2005-04. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00426673?
The interventions under investigation include: Brivaracetam (ucb34714) (DRUG).
Who is sponsoring clinical trial NCT00426673?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.